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1. Introduction
We now stand at the centenary of heparin’s discovery and can 
reflect upon a story of early difficulties, followed by many years 
of success and short periods of crisis but, throughout, heparin has 
remained available as a life-saving drug. The therapeutic use of 
heparin has been principally as an anticoagulant but, more recently 
other, non-anticoagulant activities and applications have begun to 
be explored. Heparin was discovered in 1916 [1] as “cephalin” and 
re-named “heparin” in 1918 [2], was commercialized in the early 
1920s and subsequently became a well-established anticoagulant 
drug. From the mid-1970s the numbers of reports regarding its 
fractionation and depolymerization to generate low molecular 
weight heparins (LMWs) increased, accompanied by work on 
both unfractionated heparin and derivatives that targeted non-
anti coagulant applications. Approaching the centenary, several 
publications appeared, including the review “Re-visiting the 
structure of heparin” [3] and the book “Heparin a century of progress” 
[4], that includes the well-documented “history of heparin” [5] and 
“non-coagulant effects of heparin: an overview” [6].
2. The sources of, and crisis with, pharmaceutical grade heparin
The first pharmaceutical preparations by Roche-Organon from 
bovine lung were commercialized in USA as “Liquemin” in 1939. 
In the 1950s bovine lung was replaced by porcine mucosal heparin 
(PMH) as the major source and partially by bovine mucosal heparin 
(BMH) in the 1960s [5], but BMH was withdrawn from Western 
countries during the 1990s because of potential prion contamination 
and the risk of infection with bovine spongiform encephalopathy 
(BSE), which was prevalent at that time in Europe. Concerns with 
other animal sources aroused the search for biotechnological 
heparins starting from the microbial polysaccharide K5, comprising 
a repeating disaccharide sequence [-4) D-GlcA  (1-4) GlcNAc 
 (1-], common to that of N-acetyl heparosan, the biosynthetic 
precursor of heparin. Through a combination of enzymatic and 
chemical steps, heparin anticoagulant mimetics were obtained [7,8] 
and their development has been reviewed recently [9]. A second 
crisis, in late 2007 and early 2008 mainly in the USA, was caused 
by adverse events, including fatalities, in patients treated with 
PMH contaminated arised from an “unnatural” fully O-sulfated 
chondroitin sulfate [10]. As a consequence, demand increased for 
pharmaceutical grade PMH and derived LMWHs, and provoked 
the development of more rigorous controls [11], but also raised 
concerns regarding the supply of the starting material, which is 
produced mainly in China. These events have induced EC authorities 
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On the centenary of the discovery of heparin, the International Journal of Cardiology agreed to publish a 
collection of mini reviews that summarize the historical development of this ever-young life-saving drug. The 
present articles deal not only with the historical milestones, but also with current and future perspectives 
regarding the development of heparin in terms of its structure, as well as on-going biochemical, biological 
and clinical research. Attention is focused on recent applications of heparin derivatives to non-anticoagulant 
or antithrombotic therapies, providing particular emphasis on their inhibitory activities, including their 
potential as anti-cancer agents. In the Chapter, entitled ‘Recent innovations in the structural analysis of 
heparin’, some recent technological advances are described for the problem of monitoring the purity and 
reproducibility of pharmaceutical heparin. These now permit sensitive detection of non-heparin impurities, 
as well as the detection of heparin from different animal sources, to be made in pharmaceutical heparin 
samples. In ‘Past, present, and future perspectives of heparin in clinical settings and the role of impaired renal 
function’, the author traces the history of heparin and the development of low molecular weight heparin, 
highlighting the large number of clinical trials in which it has been involved, and reviewing its efficacy among 
patients with impaired renal function. In the final chapter, ‘Old and new applications of non-anticoagulant 
heparin’, the authors survey some of the many non-anticoagulant activities of heparin and its derivatives, 
including glycol-split heparin, which has demonstrated promising activities in a wide-range of situations.
© 2016 Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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and the US FDA to consider the reintroduction of bovine heparin, 
which has been produced and clinically used continually in South 
American and other countries. Its potential re-introduction into 
Western markets was one of the topics of two recent meetings: 
“The 6th Workshop on Characterization of Heparin Products” held 
on August 6–7, 2015, in São Paulo, Brazil and the “23rd Symposium 
on Glycosaminoglycans”, which addressed the “Heparin Centenary: 
Present and Future Perspectives”, held in Milan and at Villa Vigoni, 
Loveno di Menaggio (Co), Italy on 17–19 September 2015.
3. Early clinical studies and discovery of anti-thrombin 
mechanism of action and binding sequences
The first parental preparations from canine liver, estimated to 
be around 14–15% pure, were tested in patients around 1924 with 
several side effects [12], but these were no longer present by the 
arrival of the first commercial heparin preparations in the early 
1930s [13]. Later, it was discovered [14] that heparin required a 
plasma co-factor for its anticoagulant activity, which was identified 
as antithrombin III (AT) [15]. Heparin binding to AT, discovered 
in 1973 [16], was found to increase the rate of AT inhibition of 
thrombin by up to one hundred times [17,18] and to potentiate the 
inhibition of other serine proteases involved in the coagulation 
process, as recently reviewed [19]. The most active sequence in 
heparin that is involved in AT binding and activation was identified 
in oligosaccharides derived from both enzymatic and chemical 
depolymerisation processes that unexpectedly preserved the active 
sequence, a pentasaccharide core of the AT binding region (ATBR), 
characterized by a crucial internal trisulfated glucosamine (Fig. 
1) [20–23]. Utilising the natural, high affinity components from 
oligosaccharides extracted from 50 kg of heparin, allowed the correct 
identification of an “anomalous” residue in the ATBR sequence by 
NMR spectrometry [24]. Despite this success, and the contribution 
that NMR made to the debate around GlcA and IdoA content [25] 
and conformational studies [26], these NMR results were initially 
rejected in favour of the more-doubtful measurement of sulfate 
content. 1981 could represent the year in which NMR spectrometry 
began to be used for the analysis and characterization of GAGs on a 
significant scale, a process that continues today, culminating with 
the present requirement for NMR identification of heparin-based 
drugs [27,28]. The discovery of this sequence, which is present 
in only one third of heparin chains paved the way for the search 
for LMWH. The ATBR sequence was the major one found in PMH 
[29[, but in a bovine lung heparin sample, a de-N-acetylated, re-N-
sulfated variant was identified [30]. The possible re-introduction 
of BMH, and the dearth of recent compositional studies concerning 
its ATBR containing sequences, prompted our group to compare 
the sequence profiles of pharmaceutical grade BMH and PMH 
samples selected from same producer. NMR and LC/MS analyses 
of heparin samples of their AT affinity chromatographic fractions 
and comparison of their heparinase digestion products revealed 
the main differences, consisting of lower ATBR content of BMH 
and some of its components, mainly tri-sulfated glucosamine (A*), 
despite an anti-factor Xa activity comparable to that of PMH. This 
may be explained by the presence in some BMH chains of peculiar 
ATBR sequences, such as one bearing two trisulfated glucosamine 
residues [31].
4. Low molecular weight heparins (LMWs)
The first LMW tested in clinical trials was “Fraxiparine” (Choay 
Labs) [32], prepared by gel filtration, which resulted in the loss of 
two thirds of the heparin starting material. By the 1980s, four other 
LMWs, prepared using less costly processes were commercialized 
by European companies. LMWHs currently available in the EU and 
USA, produced by partial depolymerization of pharmaceutical grade 
heparin show mean Mw between 3.5 and 6 kDa (corresponding to 
12–20 disaccharide units), comprising at least 60% material with Mw 
<8 kDa [33]. When compared to heparin, LMWs have a lower affinity 
towards plasma proteins, endothelial cells and macrophages, but 
better bioavailability and pharmacokinetics with more predictable 
dose responses [34]. The chemical-physical characterization of LMWs 
has been reviewed recently [35]. The names, brands, production 
processes and mean Mw of historical and currently available LMWs 
in the EU and USA are shown in Table 1. Each depolymerization 
process gives rise to chain-bearing, specific marker residues at the 
reducing (RE) and non-reducing (NRE) ends as shown in Fig. 2.
Some generic LMW appeared recently on the US market. Owing 
to the structural heterogeneity of heparin, the approval of these 
generic drugs by the FDA has required very complex structural 
characterizations. This has had a positive side through development 
of sophisticated survey techniques for primary chemical structure 
determination.
5. Ultra-low molecular weight heparins (uLMWHs) as 
antithrombotic
Disclosure of the ATBR pentasaccharidic sequence [23], found in an 
affinity hexasaccharide obtained by heparin depolymerization [37] 
promoted intensive synthetic programs, the most successful leading 
to the synthesis of the -methyl glycoside of the N-deacetylated-
N-sulfated natural pentasaccharide [38]. The product, endowed 
with AT binding and antithrombotic activity reached the market 
in 2001 as Fondaparinux (Aristra-Aspen), representing the first 
synthetic heparin oligosaccharide (Mr 1728 as the sodium salt) 
to be used as a drug. However, it requires an expensive synthetic 
process (about 50 steps and consequent low overall yield) and this 
has encouraged the search for less expensive leads through new 
heparin depolymerization or chemo-enzymatic processes. The 
development of a fully O-methylated O-sulfated Fondaparinux 
analogue, Idraparinux (Sanofi) was discontinued in phase III trials 
presumably due to intracranial bleeding. A biotinylated formulation, 
Idrabiotaparinux, was further clinically investigated [39]. 
Semuloparin (AV5026) is a ULMWH (Mw 2.4 kDa, corresponding 
to ~8 disaccharide units) [40], obtained by heparin through a 
modified Enoxaparin depolymerization process protecting ATBRs, 
that has been evaluated in Phase III/IV trials, but its development 
was halted in 2012. Finally, active oligosaccharides from hexa- up 
to dodecasaccharides have been obtained by a chemo-enzymatic 
approach starting from the bacterial polysaccharide K5 using a 
recombinant version of the heparan biosynthesis enzymes [41].
Fig. 1. Schematic representation of the minimal binding sequences of heparin chain 
specific for some of the target proteins. ANS: (1-4) N-sulfated -D glucosamine, ANS,6S: (1-
4) N-sulfated,6-O-sulfated -D-glucosamine, ANS,3,6S: (1-4) N-sulfated, 3-,6-O-sulfated -D-glucosamine, G: (1-4) -D-glucuronic acid, I: (1-4) -L-Iduronic acid, I2S: (1-4) 
2-O-sulfated -L-iduronic acid.
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6. Current developments
Up until today the development of these derivatives of natural, 
semisynthetic and synthetic heparin have been orientated toward 
the search for products with higher selectivity toward antithrombin.
After one hundred years of studies, new therapeutic applications 
for heparin and its derivatives are in the offing. These are no 
longer based on the ability to interact with ATBR but interactions 
with other biological targets through the identification of specific 
oligosaccharide sequences.
Considerations relating to the structure of this macromolecule, 
which inter alia is the most ionic molecule present in our organism, 
as well as the development of the knowledge resulting from scientific 
research of glycosaminoglycans, encourages us increasingly to con-
sider other potential functional activities carried out by this family 
of molecules.
Conflict of interest statment
The authors declare no competing financial interest.
References
 [1] McLean J. The thromboplastic action of cephalin. Am J Physiol. 1916; 41(2): 250-7.
 [2] Howell W H, Holt E. Two new factors in blood coagulation-heparin and pro-anti-
thrombin. Am J Physiol. 1918; p 47(3): 328-341.
 [3] Casu B, Naggi A, Torri G. Re-visiting the structure of heparin. Carbohydrate 
Research. 2015; 403: 60-68.
 [4] Heparin - A century of progress. In Lever R, Mulloy B, Page CP, editors. Heidelberg: 
Springer Science; 2012.
 [5] Barrowcliffe TW. History of heparin. In Lever R, Mulloy B, Page CP, editors. 
Heparin - A century of progress. Heidelberg: Springer; 2012; 3-22.
 [6] Lever R, Page CP. Non-anticoagulant effects of heparin: an overview. In Lever R, 
Mulloy B, Page CP, editors. Heparin - A century of progress. Heidelberg: Springer; 
2012; 281-305.
 [7] Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G et al. Heparin-like com-
pounds prepared by chemical modification of capsular polysaccharide from E. 
coli K5. Carbohydrate research. 1994; 263(2): 271-284.
 [8] Lindahl U, Li J P, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T, Emeis J 
et al. Generation of “Neoheparin” from E. c oli K5 Capsular Polysaccharide. Journal 
of medicinal chemistry. 2005; 8(2): 349-352.
 [9] Oreste P, Zoppetti G. Semi-synthetic heparinoids. In Lever R, Mulloy B, Page CP, 
editors. Heparin - A century of progress. Heidelberg: Springer; 2012; 403-422.
 [10] Guerrin M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A et al. Oversulfated 
chondroitinsulfate is a contaminant in heparin associated with adverse clinical 
events. Nature Biotechnol. 2008; 26: 669-675 Epub ahead of print.
 [11] Gray E. Standardisation of unfractionated and low-molecular-weight heparin. In 
Lever R, Mulloy B, Page CP, editors. Heparin - A century of progress. Heidelberg: 
Springer; 2012; p. 65-76.
 [12] Mason EC. A note on the use of heparin in blood transfusion. The Journal of 
Laboratory and Clinical Medicine. 1924; 10(3): 203-206.
 [13] Charles AF, Scott DA. Studies on heparin I. The preparation of heparin. Journal of 
Biological Chemistry. 1933; 102(2): 425-429.
 [14] Howell WH. The purification of heparin and its chemical and physiological reac-
tions. Bull. John Hopkins Hosp. 1928; 42: 199-206.
 [15] Abildgaard U. Highly purified antithrombin III with heparin cofactor activity 
prepared by disc electrophoresis. Scandinavian Journal of Clinical & Laboratory 
Investigation. 1968; 21(1):89-91.
 [16] Rosenberg RD, Damus PS. The purification and mechanism of action of human 
antithrombin-heparin cofactor. Journal of Biological Chemistry. 1973; 248(18): 
6490-6505.
 [17] Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature. 1973; 
246 (5432):355-357.
 [18] Rosenberg R D, Lam L. Correlation between structure and function of heparin. 
Proceedings of the National Academy of Sciences. 1979; 76(3): 1218-1222.
 [19] Gray E, Hogwood J, Mulloy B. The anticoagulant and antithrombotic mechanisms 
of heparin. In Lever R, Mulloy B, Page CP, editors. Heparin - A century of progress. 
Heidelberg: Springer; 2012; 43-61.
 [20] Lindahl U, Bäckström G, Höök M, Thunberg L, Fransson L A, Linker A. Structure of 
the antithrombin-binding site in heparin. 1979, 76(7):3198-3202.
 [21] Lindahl U, Bäckström G, Thunberg L, Leder IG. Evidence for a 3-O-sulfated 
D-glucosamine residue in the antithrombin-binding sequence of heparin. 
Proceedings of the National Academy of Sciences. 1980; 77(11):6551-6555.
 [22] Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC et al. The structure of 
heparin oligosaccharide fragments with high anti-(factor Xa) activity containing 
the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-mag-
netic-resonance studies. Biochem. J. 1981; 197:599-609.
 [23] Thunberg L, Bäckström G, Lindahl U. Further characterization of the antithrombin-
binding sequence in heparin. Carbohydrate research. 1982; 100(1):393-410.
 [24] Choay J, Lormeau JC, Petitou M, Sinay P, Casu B, Oreste P et al. Anti-Xa active 
heparin oligosaccharides. Thrombosis Res. 1980; 18:573–578.
 [25] Perlin AS, Casu B, Sanderson GR, Johnson LF. 220 MHz spectra of heparin, chon-
droitins, and other mucopolysaccharides. Canadian Journal of Chemistry. 1970; 
48:2260-2268.
 [26] Casu B, Choay J, Ferro DR, Gatti G, Jacquinet J-C, Petitou M et al. Controversial 
Glycosaminoglycan Conformations. Nature. 1986; 322:215 - 216.
 [27] Heparin sodium. European Pharmacopoeia. 8th edition. Strasbourg : EDQM 
Council of Europe. 2010; Vol. II:2390-91.
 [28] Heparin Sodium Update. Division of Drug Information - USP 35. Rockville: United 
States Pharmacopeia - U.S., 2010; Apr 7th.
 [29] Lindahl U, Thunberg L, Bäckström G, Riesenfeld J, Nordling K, Björk I. Extension 
and structural variability of the antithrombin-binding sequence in heparin. 
Journal of Biological Chemistry. 1984; 259(20):12368-76.
 [30] Loganathan D, Wan HM, Mallis LM, Linhardt RJ. Structural variation in the anti-
thrombin III binding site region and its occurrence in heparin from different 
sources. Biochemistry. 1990; 29(18):4362-68.
Table 1
API name Speciality – Pharmaceutical Production process KDa
Ardeparin Normiflo – Hepar-Pfizer Peroxide 6.0
*Bemiparin  Ivor – Sigma tau Alkali in non-aqueosus medium 3.6
Certoparin Sandoz – Novartis Isoamylnitrate 
Dalteparin Fragmin – Kabi/Pfizer Controlled nitrous acid 6.0
Enoxaparin Lovenox/Clexane – Sanofi Aventis Benzylation followed by alkali treatment 4.5 
Nadroparin  Fraxiparin – Choay/Aspen Controlled nitrous acid 5.0
Parnaparin Fluxum- – Wasserman Peroxide 4.0
Reviparin Clivarin – Knoll/Abbott Nitrous acid followed by chromatography 4.0
Tinzaparin Immohep/Logiparine – Novo/Leo Enzymatic  6.0
CY 222 Fraxiparin – Choay Gel filtration 3.5
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